INO
Inovio Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.
Market Cap: 2.69 Billion
Primary Exchange: NASDAQ
Website: http://www.inovio.com/
Shares Outstanding: 273 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.7200180964176657
Sector: Manufacturing
Industry: Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Ethical Flags
Longest drawdown: 1670 trading days
From: 2014-03-19 To: 2020-05-19
Lowest Point:
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
via: PR Newswire at 2019-06-10 05:00:00:000
PLYMOUTH MEETING, Pa. , June 10, 2019 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Med… read more...
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
via: PR Newswire at 2019-06-10 05:00:00:000
PLYMOUTH MEETING, Pa. , June 10, 2019 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Med… read more...
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
via: PR Newswire at 2019-06-10 05:00:00:000
PLYMOUTH MEETING, Pa. , June 10, 2019 /PRNewswire/ --Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Med… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2014-06-06 | 4.0 | 1.0 | 4.0 |